In Brief: Teva/Marion Merrell Dow
Executive Summary
Teva/Marion Merrell Dow: Sign letter of intent to collaborate on late-stage development and North American marketing of Teva's Copaxone (copolymer-1) for multiple sclerosis. Teva announced in October after Phase III results were released that it expects to submit the Copaxone NDA to FDA and to make comparable regulatory filings in other major markets "by the middle of 1995" ("The Pink Sheet" Oct. 17, 1994, T&G-4). Copaxone is being studied for its ability to lessen the number of exacerbations and the extent of disability in MS patients with the relapsing/remitting form of the disease. The drug is available in the U.S. under a Treatment IND through Teva's Lemmon generics subsidiary...
|
Teva/Marion Merrell Dow: Sign letter of intent to collaborate on late-stage development and North American marketing of Teva's Copaxone (copolymer-1) for multiple sclerosis. Teva announced in October after Phase III results were released that it expects to submit the Copaxone NDA to FDA and to make comparable regulatory filings in other major markets "by the middle of 1995" ("The Pink Sheet" Oct. 17, 1994, T&G-4). Copaxone is being studied for its ability to lessen the number of exacerbations and the extent of disability in MS patients with the relapsing/remitting form of the disease. The drug is available in the U.S. under a Treatment IND through Teva's Lemmon generics subsidiary.... |